Emulate Inc. closes $82M Series E to fund expansion of ‘organ-on-a-chip’ products
TechCrunch
SEPTEMBER 7, 2021
A lot of that growth will depend on the potential for an organ-on-a-chip to disrupt the preclinical side of the drug testing process. And that itself depends a lot on how the FDA views data collected on that platform. . There is evidence the company has worked closely with the FDA in the past.
Let's personalize your content